GeneVentiv Therapeutics Revenue

About GeneVentiv Therapeutics

At GeneVentiv, we transform curiosity into innovation — and innovation into cures for patients who, until now, had no hope. We are pioneering therapies that reach every patient within a disease area, not just a select few. Our lead program, GENV-HEM, is an AAV-based gene therapy expressing Factor Va that treats hemophilia A or B, even in patients with inhibitors. Factor Va is natively produced in hepatocytes and secreted efficiently, so GENV-HEM is not subject to the durability issues seen with the current Factor VIII gene therapy. Our goal is a one-time treatment for all hemophilia patients — relieving the burden of regular injections and infusions. Unlike other programs, GENV-002 is the first gene therapy designed for both infants and adults with Pompe — reaching patients up to 18 years earlier than competitors. Our goal is to eliminate 4–6 hour bi-weekly infusions and help children with Infantile Pompe take their first steps — into a new life Join us as we carve a path to cures for hemophilia and Pompe — delivered through single, life-changing infusions. To learn more about GeneVentiv, visit www.geneventiv.com.

View contact profiles from GeneVentiv Therapeutics